Showing results (101-110 of 154) with videos related to
Sort By:
Pageof 16
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 27, 2019
A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 InfectionEdwin DeJesus, Sara Harward, Roxanne C Jewell, et al.BMC Infectious Diseases|January 14, 2005
Substituting abacavir for hyperlipidemia-associated protease inhibitors in HAART regimens improves fasting lipid profiles, maintains virologic suppression, and simplifies treatmentPhilip H Keiser, Michael G Sension, Edwin DeJesus, et al.Eclinicalmedicine|May 18, 2023
Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trialsPaul E Sax, José R Arribas, Chloe Orkin, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|February 16, 2013
Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRKJürgen K Rockstroh, Edwin DeJesus, Jeffrey L Lennox, et al.Lancet (London, England)|September 5, 2017
Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trialPaul E Sax, Anton Pozniak, M Luisa Montes, et al.AIDS (London, England)|March 21, 2003
A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapyJacob P Lalezari, Joseph J Eron, Margrit Carlson, et al.Journal of Hepatology|November 28, 2012
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trialMaribel Rodriguez-Torres, Eric Lawitz, Kris V Kowdley, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|October 15, 2019
Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority TrialCissy Kityo, Debbie Hagins, Ellen Koenig, et al.The Lancet. HIV|June 22, 2018
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trialEric S Daar, Edwin DeJesus, Peter Ruane, et al.The Journal of Infectious Diseases|March 28, 2013
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 resultsJoel E Gallant, Ellen Koenig, Jaime Andrade-Villanueva, et al.Pageof 16